Enteris Biopharma

Enteris Biopharma is a privately held biopharmaceutical company headquartered in Boonton, New Jersey, in the United States. The company is known for its work in oral drug delivery, particularly its Peptelligence platform, which is designed to enable the oral administration of peptide and small-molecule therapeutics that would otherwise require injection. This technology addresses one of the long-standing challenges in pharmaceutical development: the poor oral bioavailability of large-molecule drugs such as peptides and proteins. Enteris positions itself as a drug delivery and formulation partner rather than a traditional pharmaceutical manufacturer. It works with pharmaceutical and biotechnology companies to apply its Peptelligence technology to their proprietary compounds, aiming to convert injectable products into oral dosage forms. The company's pipeline and partnerships have historically focused on therapeutic areas including endocrinology, metabolic disease, and women's health, among others. The company is headquartered in Boonton, New Jersey, and operates primarily in the United States. It is a private entity and has been involved in licensing and collaboration agreements with larger pharmaceutical partners. Enteris Biopharma has also pursued its own internal development programs, though its business model emphasizes technology licensing and formulation services. As a specialist in oral peptide delivery, Enteris occupies a niche within the broader biopharmaceutical services and drug delivery sector. Its Peptelligence platform combines permeation enhancers and enteric coating technologies to improve the uptake of peptides across the intestinal wall. The company has presented data at scientific conferences and has entered into feasibility and development agreements with multiple partners. Because Enteris is a private company, detailed financial information and ownership structure are not publicly disclosed in the same manner as for public corporations. The company continues to operate from its New Jersey headquarters and remains active in the drug delivery space.

Enteris Biopharma is a biopharmaceutical company based in Boonton, New Jersey, United States. The company was established to develop and commercialize oral drug delivery technologies, with a particular focus on peptides and other molecules that are typically administered by injection. Its core technology, known as Peptelligence, is designed to enhance the oral bioavailability of peptide and small-molecule drugs by combining permeation enhancers with enteric coating and other formulation approaches. Enteris has operated as a private company and has pursued a business model centered on technology licensing and collaborative development agreements with pharmaceutical and biotechnology partners. Rather than marketing its own branded pharmaceutical products on a large scale, the company has primarily sought to apply its Peptelligence platform to partner compounds, aiming to create oral versions of injectable drugs. This approach positions Enteris within the drug delivery and formulation services segment of the life sciences industry. Over the years, Enteris has entered into feasibility studies and development agreements with various pharmaceutical companies. These collaborations typically involve evaluating whether a partner's peptide or small-molecule drug can be formulated for oral delivery using the Peptelligence technology. The company has also worked on internal programs in therapeutic areas such as metabolic disease and women's health, though specific program details and outcomes are not widely publicized. The company is headquartered in Boonton, New Jersey, and its operations are primarily based in the United States. As a private entity, Enteris does not publicly report financial results in the manner of a publicly traded corporation, and its ownership structure has not been widely disclosed. The company remains active in the oral drug delivery field, continuing to promote its Peptelligence platform to potential partners. Enteris Biopharma's history reflects the broader trend in the pharmaceutical industry toward developing patient-friendly oral alternatives to injectable biologics and peptides. While the company is not a large multinational, it occupies a specialized niche in drug delivery technology, competing with other formulation and delivery companies that offer similar enabling platforms.

Specialist drug delivery company focused on enabling oral administration of peptides and small molecules through its Peptelligence technology.

• Peptelligence

  Oral peptide and small-molecule drug delivery platform that combines permeation enhancers and enteric coating to improve oral bioavailability.

• Unconfirmed

  Reported2021.05.17

  Enteris BioPharma launches CDMO business[3]Enteris BioPharma推出CDMO业务prnewswire.com

  SWK Holdings said its subsidiary Enteris BioPharma had launched its contract development and manufacturing (CDMO) business, offering development and manufacturing capabilities from bench to market.

• Unconfirmed

  Reported2021.05.17

  Enteris BioPharma completes manufacturing facility expansion[3]Enteris BioPharma推出CDMO业务prnewswire.com

  SWK Holdings said its subsidiary Enteris BioPharma had completed an expansion of its manufacturing facility, enabling it to produce clinical-trial material through Phase 3 and products for commercial launch.

• 2020.05.04

  Reported2020.05.04

  Enteris BioPharma appoints Rajiv Khosla as CEO[4]Enteris BioPharma 任命 Rajiv Khosla 为首席执行官prnewswire.com

  Enteris BioPharma announced Rajiv Khosla's appointment as chief executive officer, effective immediately, replacing Joel Tune.

• 2020.01.27

  Reported2020.01.27

  Enteris BioPharma receives Best of Boonton Award[5]Enteris BioPharma 获得 Boonton 最佳奖prnewswire.com

  Enteris BioPharma announced that it had received the 2019 Best of Boonton Award in the Pharmaceutical Company category from the Boonton Award Program.

Read more

1. 1Enteris Biopharma (United States) - Wikidatawikidata.org
2. 2Enteris Biopharma official websiteenterisbiopharma.com
3. 3Enteris BioPharma推出CDMO业务prnewswire.com
4. 4Enteris BioPharma 任命 Rajiv Khosla 为首席执行官prnewswire.com
5. 5Enteris BioPharma 获得 Boonton 最佳奖prnewswire.com
6. 6Enteris BioPharma Receives 2021 Best of Boonton Awardprnewswire.com